Randomized, Single-Blind, Parallel Study of the Effectiveness and Safety of Solifenacin versus Propiverine in the Treatment of Overactive Bladder.

about

Randomized, Single-Blind, Parallel Study of the Effectiveness and Safety of Solifenacin versus Propiverine in the Treatment of Overactive Bladder.

Item

http://www.wikidata.org/entity/Q40216118

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Randomized, Single-Blind, Para ...... eatment of Overactive Bladder.

@en

type

Item

label

Randomized, Single-Blind, Para ...... eatment of Overactive Bladder.

@en

prefLabel

Randomized, Single-Blind, Para ...... eatment of Overactive Bladder.

@en

P1476

Randomized, Single-Blind, Para ...... eatment of Overactive Bladder.

@en

P2093

Takao Kamai

http://www.w3.org/2001/XMLSchema#string

Takehiko Fukuda

http://www.w3.org/2001/XMLSchema#string

Tomonori Yamanishi

http://www.w3.org/2001/XMLSchema#string

Tomoyuki Uchiyama

http://www.w3.org/2001/XMLSchema#string

P2860

Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'.

Which muscarinic receptor is important in the bladder?

Muscarinic receptor antagonists for overactive bladder.

Defining overactive bladder as hypersensitivity.

A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials.

Reliability and validity of King's Health Questionnaire in patients with symptoms of overactive bladder with urge incontinence in Japan.

Validation of the urgency perception scale.

Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial.

Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.

A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder.

P304

11-16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1757-5672.2012.00157.X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26663242

http://www.w3.org/2001/XMLSchema#string